-
Local pharmaceutical companies accelerate the development of TCR-T therapy The market size may exceed 104 billion yuan
Time of Update: 2022-09-08
Drug research and development (Photo source: Pharmaceutical Network) At present, TCR-T therapy mainly targets the solid tumor market and has become a research hotspot internationally, but the global TCR-T therapy industry is still in the experimental research stage .
-
The performance of the medical device sector in the first half of the year was outstanding, and new medical infrastructure will become an important development line in the future
Time of Update: 2022-09-08
Judging from the year-on-year growth rate of net profit, the net profit attributable to the parent company of 6 medical device companies has increased by more than 100% year-on-year, including Yahuilong, Mingde Bio, Aotai Bio, Kaipu Bio, Daan Gene and Wanfu Bio, etc.
-
State Food and Drug Administration: Promotion meeting for quality supervision of selected drugs in centralized procurement was held
Time of Update: 2022-09-08
Huang Guo emphasized that the drug regulatory authorities should be brave in their responsibilities, fulfill their responsibilities, pay attention to details, strengthen risk investigation and disposal, and make greater contributions to the overall stability of the country with the stability of drugs in the centralized procurement process.
-
With the enthusiasm of pharmaceutical companies for research and development, the level of children's medication in China is constantly improving
Time of Update: 2022-09-08
For example, since 2008, the Health Commission has invested 600 million yuan through the special project of new drugs to support the research and development of children's drugs and clinical research; The National Children's Medical Center was established, and 23 pediatric medical institutions were united to establish the "China Pediatric Population Drug Clinical Trial Collaboration Network" to promote pediatric clinical trials.
-
The pharmaceutical industry will maintain a high boom development trend for a long time, and these three major sectors deserve attention
Time of Update: 2022-09-08
CXO CXO Judging from the performance of CXO companies that released semi-annual reports, the net profit attributable to the mother of WuXi AppTec, Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, Yaokang Biologics and other companies has exceeded 50% year-on-year growth.
-
131 million! At the end of August, another pharmaceutical company launched a merger and acquisition
Time of Update: 2022-09-08
On August 29, Jiuqiang Bio announced that the company and Xinyu Yuanlang Management Consulting Partnership (hereinafter referred to as "Yuanlang Management") signed an equity transfer agreement on August 29, 2022, and about 131 million yuan was transferred to Fuzhou Maixin Biotechnology Development Co.
-
More than half of pharmaceutical companies have achieved performance growth, and the CXO field will benefit in the long run
Time of Update: 2022-09-08
In addition to WuXi AppTec, the net profit attributable to the parent of CXO companies such as Boteng Shares, Gloria Ying, Baicheng Pharmaceutical, and Yaokang Biotech has increased by more than 50% year-on-year.
-
The 10 billion ophthalmic drug market has made waves again, and the competition will be more intense!
Time of Update: 2022-09-08
According to industry statistics, since 2022, 5 ophthalmic drugs (15 product specifications) have been approved in China, among which diquafosol sodium eye drops from Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, and hydrochloric acid from Sichuan Heyi Pharmaceutical Lidocaine ophthalmic gel is the first imitation in China .
-
Interpreting the pattern of the children's drug market, the track overtaking focuses on the segmentation
Time of Update: 2022-09-07
Kinsey's pediatric drugs are not used in the two major disease areas of breathing and digestion, and its core products are recombinant human growth hormone for childhood short stature, which extends the layout of height management, sexual development, newborns, child care, children's neuropsychiatric and other fields.
-
A large number of pharmaceutical companies want to take advantage of this model to achieve "curve overtaking" on the innovative drug track
Time of Update: 2022-09-07
License-in is a popular equity trading model in the domestic biomedical industry in recent years, and the reason why it is sought after by pharmaceutical companies is mainly because on the high-risk and high-input innovative drug track, this is a shortcut with less investment, fast effect, and even "curve overtaking".
-
The interim report card of 570 pharmaceutical companies was announced, and the pharmaceutical company earned a net profit of over 10 billion yuan
Time of Update: 2022-09-07
For the reason for the surge in performance in the first half of the year, Jiu'an Medical attributed it to the substantial growth in demand for antigen detection kit products in the United States .
-
Walking at the grassroots level into the enterprise Zhang Wei, president of the China Drug Supervision and Administration Research Association, and his party came to Qianhui for research and guidance
Time of Update: 2022-09-07
On the afternoon of August 19, 2022, Zhang Wei, president of the China Drug Administration and Research Association and former secretary general of the State Pharmacopoeia Commission, Shi Liqiang, vi
-
@ Shanxi people, multiple unit price thousands of yuan drug price reduction!
Time of Update: 2022-09-07
Also on the 28th, Shanxi Pharmaceutical And Device Center issued a notice, according to the application of enterprises, Chengdu Diao Jiuhong Pharmaceutical Factory and other 26 enterprises 56 drug hanging net price adjustment, from the list of points of view, many varieties of price reduction is relatively large, For example, the compound blue palm fruit tablets of Chengdu Diao Jiuhong Pharmaceutical Factory dropped from the original 35.
-
In order to improve and enhance the competitiveness of enterprises, another pharmaceutical company has entered the field of private equity
Time of Update: 2022-09-07
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contribution .
The initial investment amount is 200 million yuan, accounting for 40% of the total subscribed capital contribution .
-
Opinions on further strengthening the popularization of science and technology in the new era
Time of Update: 2022-09-07
Recently, the General Office of the CPC Central Committee and the General Office of the State Council issued the "Opinions on Further Strengthening the Popularization of Science and Technology in the
-
The State Food and Drug Administration investigated the quality and safety supervision of color contact lenses
Time of Update: 2022-09-07
drug Xu Jinghe pointed out that color contact lenses belong to the third class of medical devices with high risk, and according to the regulations on the supervision and administration of medical devices, they belong to products that "require special measures to be strictly controlled and managed".
-
Jiao Hong presided over the symposium on special rectification of drug safety
Time of Update: 2022-09-07
On August 31, Jiao Hong, director of the State Food and Drug Administration, presided over a symposium on special rectification of drug safety in Beijing, listening to the special rectification of dr
-
National Medical Insurance Bureau: In the first seven months of the country, outpatient expenses were directly settled across provinces by 14.0422 million person-times
Time of Update: 2022-09-07
In order to facilitate the insured to directly settle the treatment costs related to 5 kinds of outpatient chronic and special diseases across provinces, the APP of the national medical insurance service platform has added query functions such as the notification letter of inter-provincial outpatient chronic and special diseases .
-
Under the pressure of collection and medical insurance, local pharmaceutical companies are actively looking for new growth points
Time of Update: 2022-09-07
In April, ZHAOYAN New Drug, a leading CRO company, announced that on April 28, 2022, the company entered into an equity transfer agreement with Guanfang Group and Xieer Yunkang, which agreed that the company intended to acquire a 60% and 40% equity interest in Weimei Biotechnology for 975 million yuan.
-
Focusing on innovation, a large number of pharmaceutical companies ushered in new growth in the first half of the year!
Time of Update: 2022-09-07
It is understood that in the first half of 2022, the sales revenue of Fangsheng Pharmaceutical Yizhi wheat cloth tablets successfully exceeded 100 million, which has exceeded the annual sales revenue of 2021, in addition, the sales revenue of innovative Chinese medicine children's Jingxing cough granules also increased by more than 800% in the same period.
